Skip to content
The Policy VaultThe Policy Vault

Omnipod dash intro kit (gBlue Cross Blue Shield of Montana

diabetes mellitus requiring insulin therapy

Initial criteria

  • ONE of the following:
  • A. Patient has been using the requested product within the past 90 days AND is at risk if therapy is changed OR
  • B. Patient currently has an insulin pump (e.g., Omnipod Eros, Minimed, Guardian) that is not functioning properly AND is past warranty OR
  • C. ALL of the following:
  • 1. Patient has diabetes mellitus AND requires insulin therapy AND
  • 2. BOTH of the following:
  • A. Patient is on an insulin regimen of ≥3 injections per day AND
  • B. Patient performs ≥4 blood glucose tests per day or is using continuous glucose monitoring (CGM) AND
  • 3. Patient has completed a comprehensive diabetes education program AND
  • 4. Patient has demonstrated willingness and ability to play an active role in diabetes self-management AND
  • 5. Patient has ONE of the following while compliant on optimized multiple daily insulin injection regimen:
  • A. HbA1C > 7% OR
  • B. History of recurring hypoglycemia OR
  • C. Wide fluctuations in blood glucose before mealtime OR
  • D. Dawn phenomenon with fasting blood sugars frequently >200 mg/dL OR
  • E. History of severe glycemic excursions AND
  • 2. ONE of the following:
  • A. Patient age is within manufacturer recommendations for the requested indication OR
  • B. There is support for use for the patient’s age
  • For members residing in Ohio, fully insured or HIM Shop (SG) plans require:
  • 1. Patient does not have any FDA labeled contraindications to the requested agent AND
  • 2. ONE of the following:
  • A. Patient has another FDA labeled indication for the requested agent and route of administration OR
  • B. Patient has another indication supported in compendia OR
  • C. Prescriber has submitted two peer-reviewed medical journal articles supporting the proposed use

Reauthorization criteria

  • Same clinical criteria as initial approval may apply at renewal to confirm continued clinical appropriateness

Approval duration

12 months